Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AZD5055 in Healthy Japanese and Chinese Volunteers
NCT05955183Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in idiopathic pulmonary fibrosis (IPF) comparing AZD5055 with Placebo (2 arms). Primary endpoint: Number of participants with adverse events at Day 15. Started Jul 2023; status: completed.
02
Drugs
AZD5055
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT05955183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05955183.